AccessibilityHelpAbout Us
Lobe Sciences logo

Lobe Sciences(OTC) LOBEF

Market Cap$15.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-90%
5 Year-78%
1 Year+34%
1 Month-14%
$0.05
+0.00%
+0.00Today
Lobe Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.052026-09-24
Lobe Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.16%USD 0.052026-09-17
1 month-14.26%USD 0.062026-08-25
3 month-15.28%USD 0.062026-06-26
Year to date+45.06%USD 0.032025-12-31
1 year+33.78%USD 0.042025-09-24
3 year+206.13%USD 0.022023-09-25
5 year-77.82%USD 0.232021-09-24
Since inception-89.6%USD 0.482019-10-04

Lobe Sciences Financials at a Glance

Market Cap

$15.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$5.17M

EPS (TTM)

-$0.02

P/E Ratio

-3.33

Dividend

$0.00

Beta (Volatility)

0.31 (Low)

Price

$0.05

Volume

10,500

Open

$0.04

Previous Close

$0.05

Daily Range

$0.04 - $0.05

52-Week Range

$0.02 - $0.11

Estimated Earnings Date

Dec 28, 2026

LOBEF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lobe Sciences

Lobe Sciences Ltd. is a life sciences company dedicated to researching and developing psychedelic-based medicines. The company focuses on psilocybin-derived treatments combined with N-acetylcysteine, targeting mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD).

Products and Services
  • Psilocybin-derived treatments for mTBI and PTSD
  • Combination therapies with N-acetylcysteine
  • Specialized devices for drug administration efficiency
Growth Outlook
  • Significant market potential in psychedelic medicine sector
  • Increasing acceptance of alternative therapies in healthcare
  • Ongoing research may lead to breakthrough treatments
Financial Highlights
  • Recent quarterly net income of -$529,936
  • Cash and short-term investments of $5,210,418
  • Current ratio of 2.38 indicates strong liquidity position
Lobe Sciences Ltd. operates in the burgeoning field of psychedelic medicine, which is gaining traction as a viable treatment option for various mental health conditions. The company's focus on innovative therapies positions it well within a rapidly evolving market. Recent financial data indicates a commitment to research and development, with substantial investments in therapeutic advancements. The liquidity position, as evidenced by a current ratio of 2.38, suggests that the company is well-equipped to manage its short-term obligations while pursuing its long-term goals. As the acceptance of psychedelic therapies grows, Lobe Sciences Ltd. may be poised for significant growth in the coming years.
AI Generated • Sep 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Frederick D. Sancilio, PhD

Website

www.lobesciences.com

Headquarters

Vancouver, BC V6G 3B7, CA

LOBEF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-338.76%

Return on Capital

-158.97%

Return on Assets

-93.41%

Earnings Yield

-30.03%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

308.18M

Volume

10.50K

Avg. Volume

52.93K

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$6.86M

EBITDA

-CA$6.85M

Operating Cash Flow

-CA$3.74M

Capital Expenditure

-CA$4.00

Free Cash Flow

-CA$3.74M

Cash & ST Invst.

CA$5.21M

Total Debt

CA$338.62K

Lobe Sciences Performance Analysis

Lobe Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31CAD 0N/A
20232023-08-31CAD 624,146N/A
20242024-08-31CAD 100,098-84.0%
20252025-08-31CAD 0N/A
Lobe Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31N/A
Q12025-11-30N/A
Q22026-02-28N/A
Q32026-05-31N/A
Lobe Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31CAD -0.25N/A
20232023-08-31CAD -0.03-86.8%
20242024-08-31CAD -0.03-20.6%
20252025-08-31CAD -0.02-13.9%
Lobe Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-08-31-70.6%
Q12025-11-3060.9%
Q22026-02-28-94.1%
Q32026-05-3171.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$15.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-CA$529.94K

+46.2%

EBITDA

-CA$1.18M

-18.5%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$5.21M

-34.6%

Total Debt

CA$338.62K

-86.3%

Accounts Receivable

CA$8.91K

+85.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

-100.0%

Short Term Debt

CA$338.62K

-47.2%

Return on Assets

-93.41%

N/A

Return on Invested Capital

-2.14%

N/A

Free Cash Flow

-CA$707.93K

-73.4%

Operating Cash Flow

-CA$707.92K

-73.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCLOFPharmaCielo Ltd.
$0.04-2.70%
BBRRFBlueberries Medical Corp.
$0.01+0.00%
BUDZWEED, Inc.
$0.03+0.00%
CANNTrees Corporation
$0.02+10.40%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About LOBEF

What is the current price of Lobe Sciences?

Lobe Sciences is trading at $0.05 per share.

What is the 52-week range for Lobe Sciences?

Over the past 52 weeks, Lobe Sciences has traded between $0.02 and $0.11.

How much debt does Lobe Sciences have?

As of the most recent reporting period, Lobe Sciences reported total debt of CA$245.65K.

How much cash does Lobe Sciences have on hand?

Lobe Sciences reported CA$1.09M in cash and cash equivalents in its most recent financial results.

What is Lobe Sciences’s dividend yield?

Lobe Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services